Puri Gopal, Ranjan Piyush, Singh Brijesh Kumar, Khadgawat Rajesh, Damle Nishikant, Priyadarshini Pratyusha, Agarwal Shipra, Das Chandan J, Sharma Kanika, Singh Ankita, Chumber Sunil
Department of Surgical Disciplines, AIIMS, New Delhi, India.
Department of Endocrinology, AIIMS, New Delhi, India.
World J Surg. 2025 Jul;49(7):1811-1819. doi: 10.1002/wjs.12627. Epub 2025 Jun 4.
Giant parathyroid adenomas represent a distinct clinical entity forming a subset under primary hyperparathyroidism (PHPT). They comprise lesions weighing more than 3.5 g. Our study aims to determine the clinical presentation, biochemical profile, outcomes, and pathological characterization of patients with giant parathyroid adenoma.
Retrospective review of data of patients who underwent parathyroid surgery between January 1995 and December 2022 by a single surgeon. A total of 561 patients were identified, and out of these, 78 had glands measuring more than 3.5 g.
The mean age was 42 years, and 51 (65%) were females. The most common complaint was bone pain (46%), followed by renal calculi (38%), with 15 (19%) patients presenting with hypercalcemic crisis. Median calcium value was 12.3 mg/dL, with median PTH, vitamin D, and ALP of 1025 pg/mL, 23 ng/mL, and 664 U/L, respectively. Fifty-three (68%) patients underwent focused parathyroidectomy, and 22 (28%) underwent neck exploration, with median postoperative calcium and PTH being 8.35 mg/dL and 37.8 pg/mL, respectively. The median weight was 7 g with a range from 3.58 g to a whopping 31 g. Symptomatic postoperative hypocalcemia was seen in 54 (69%), with 28 (36%) requiring intravenous calcium supplementation, and this was positively correlated with the preoperative ALP and PTH values.
Giant parathyroid adenomas present with florid symptoms with hypercalcemia and often hypercalcemic crisis. The biochemical workup, localization, and surgical management are similar to any other case of PHPT. Postoperatively these patients are prone to hypocalcemia, and the intravenous requirement of calcium can be predicted by preoperative ALP levels.
巨大甲状旁腺腺瘤是原发性甲状旁腺功能亢进症(PHPT)中的一个独特临床实体,属于其中的一个亚组。它们包括重量超过3.5克的病变。我们的研究旨在确定巨大甲状旁腺腺瘤患者的临床表现、生化特征、治疗结果和病理特征。
回顾性分析1995年1月至2022年12月间由单一外科医生进行甲状旁腺手术的患者数据。共识别出561例患者,其中78例腺体重量超过3.5克。
平均年龄为42岁,51例(65%)为女性。最常见的主诉是骨痛(46%),其次是肾结石(38%),15例(19%)患者出现高钙血症危象。钙的中位数为12.3毫克/分升,甲状旁腺激素(PTH)、维生素D和碱性磷酸酶(ALP)的中位数分别为1025皮克/毫升、23纳克/毫升和664单位/升。53例(68%)患者接受了甲状旁腺聚焦切除术,22例(28%)接受了颈部探查,术后钙和PTH的中位数分别为8.35毫克/分升和37.8皮克/毫升。中位数重量为7克,范围从3.58克到高达31克。54例(69%)患者术后出现有症状的低钙血症,28例(36%)需要静脉补钙,这与术前ALP和PTH值呈正相关。
巨大甲状旁腺腺瘤表现为明显的高钙血症症状,常伴有高钙血症危象。生化检查、定位和手术管理与PHPT的任何其他病例相似。术后这些患者易发生低钙血症,术前ALP水平可预测钙的静脉需求量。